AI, digital infra, and govt policies aiding India's leading hospitals and pharma firms to

India’s hospital chains and pharmaceutical firms are moving beyond volume-led expansion towards a more disciplined, technology-enabled and quality-led growth model, two separate Deloitte India surveys, the India Hospital Survey: FY27 Outlook and the Indian Pharmaceutical Industry Survey: FY27 Outlook, suggest. The findings from the.

India’s healthcare and life sciences story is entering a defining decade. “Together, these trajectories capture the growing potential of India: a nation moving from manufacturing medicines for the world to developing the therapies, technologies and care models the world will increasingly depend on," he.

What Happened

In case of pharmaceuticals, the survey suggests that Indian companies are specifically prioritising research on biologics and biosimilars, New Chemical Entities (NCEs) and digital-enabled drug discovery in the near term. In pharmaceuticals sector, India’s STEM talent base, growing CDMO capacity and an.

• Our hospital sector is projected to grow by 10 to 15 percent in FY27, backed by a wider insurance coverage and a decisive shift towards AI-enabled specialised care.

• On the hospital side, the 10–15% growth anticipated in FY27 is supported by rising insurance penetration, growing demand for organised healthcare and continued bed expansion, with private equity and internal funding supporting future growth.

• According to Deloitte, hospital bed density in India remains at 1.6 per 1,000 people, signalling significant headroom, especially beyond metro markets.

Key Details

Noting that out-of-pocket healthcare expenditure is down from 62.6% (FY15) to 39.4%(FY22) on rising insurance penetration, the report says the private sector now accounts for approximately 65% of hospital beds.

• A looming global patent cliff worth over $200 billion was seen as another opportunity for Indian pharma manufacturers.

• The pharma exports have surged approximately 16-fold from $1.9 billion (FY01) to over $31 billion (FY26), reaching more than 190 countries, the Deloitte report points out.

• India is the world’s third-largest producer of pharmaceuticals by volume and 11th by value and has the highest number of US FDA-approved manufacturing plants outside the United States.

What Reports Say

Coverage of the story so far points to:

• Continued reporting by Fortune India as more details emerge